Quarterly Results June 30, 2026

NOVYRA PHARMACHEM LIMITED CIN NO. :- L21001GJ1987PLC171085 August 14, 2026 The General Manager-Listing Corporate Relationship Department BSE Limited, Ground Floor, P.J. Towers, Dalal Street, Mumbai-400001 Scrip Code: - 519353 Dear Sir/Madam, Sub: OQutcome of the meeting of the Board of Directors held on August 14, 2026 Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015 Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held on today ie. Friday, August 14, 2026 at the Registered Office of the Company inter- alia has, considered and approved the following: - 1. Un-Audited Financial Results of the Company for the Quarter ended June 30, 2026, along with Auditors’ Limited Reports, in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations. 2. Reviewed the business of the company. The Board Meeting commenced at 05:30 P.M. and concluded at 06:00 p.m. You are requested to take the above information on records and disseminate the same on your respective websites. Thanking you, Yours faithfully, For, Novyra Pharmachem Limited (formerly known as Bansisons Tea Industries Ltd ) For, Novyra Pharmachem Limited Proit 0o pmelity Director/Autho. Signatory Anilkumar Mohanbhai Amreliya Director DIN : 11339148 RS No. 432, TP Scheme No. 3, F P No. 89/A, City Survey No. 3763, Plot No. C, Palky Plot No. A, Ground Floor, Back Side, Pavthawala Compound, B/h Zenith Mill, Vasta Devdi Road, Surat- 395004, Gujarat, India NOVYRA PHARMACHEM LIMITED R'S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India, 395004 CIN : L21001GJ1987PLC171085 Reporting of Segment wise Revenue, Results and Capital Employed along financial results for the Quarter Ended on June 30, 2026 per share data) SEne Quarter Ende The Year Ended 30/06/2026 31/03/2 30/06/2025 31/03/2026 Date of start ofr eporting period 01/04/2026 01/01/2026 01/04/2025 01/04/2025 Date of end of reportingp 30/06/2026 31/03/2 30/06/2025 31/03/2026 Whether results are audited or unaudited Unaudited Audite: Unaudited Audited Nature of report standalone or consolidated Standalone Standalone Standalone Standalone [Segment Revenue (net sale/income from each segment should be disclosed under this head) (@) _|segment- Pharma 72,61 1.00 B 1.00 (b)__|Segment - Real Estate - 0.50 - 350 (0)__|Segment - Tea Estate - 8.94 - 12.25] (@) [Segment - Unallocable - - 5.00 - Total] 172,61 10.44 3.00) 16.75 Less: Inter Segment Revenve - - - Net sales/income From Operations 172.61 10,44 3.00 16.75 5 [sesment Results (Profit)(+)/ Loss (-) before tax and interest from Each segment)# (@) |segment - Pharma (53] .00 .00 (b)__[segment - Real Extate - .50 B 3.50 () |segment - Tea Estate g (349.39) - (446.64) (@) [segment - Unallocable (.28) (85.38) ©.77) (95.24)| Total (1.99) (533.27) ©77) (537.38 [Finance Cost Other Un-allocable Expenditure net off Un-allocable income - - Total Profit Before Tax (1.99) (533.27)| ©.77) (537.39) 3 |capital Employed (Segment assets - Segment Liabilities) 3(1)_|Segment Assets (&) __[segment - Pharma 197.39 1.08 g .08 (b)__|segment - Real Estate 21.02 4427 13.74 44.27) (<) __|segment - Tea Estate 57.03 14041 549,16 74.09 (d)__[segment - Unallocable 16.75 26,44 53,44 26.44) Total 332.19 212.20 616.34 145.88 3(2) _|segment Liabilities () _[segment - Pharma. 280,15 82,34 8234 82,34 (b) _|segment - Real Estate - B (©)_[seqment - Tea Estate B 0.36) (d)__|segment - Unallocable @.21) ZE) 2284 44 Total 271.98 8668 104.82 86.68 o For, Novyra Bharmactienety Pt Fhavel ity DireatosiAutianSignatary Director| DIN: 11339148 NOVYRA PHARMACHEM LIMITED RS No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004 CIN : L21001GJ1987PLC171085 Statement of unaudited Standalone Financial Results for the Quarter ended June 30, 2026 Revenue From Operations (a) Revenue From Operations 17261 10.44] | 10.44] (b) Other Income - | 3.00 631 Total Revenue from operations (net) 172.61 10.44] 3.00] 16.75 Expenditure B (a) Cost of materials consumed B | B ] (b) Purchases of stock-in-trade 189.13] ] i B (c) Changes in inventories of finished goods, work-in- _progress and -17.81 -] - - stock-in-trade (d) Employee benefit expense 0.60, 11.80] 1.41 15.06 (e) Finance Costs -] -| - -} (e) Depreciation and amortisation expense 0.30] 0.73] 0.72] 2.89) (f) Other Expenses 2.38 531.73 1.64] 536.17 Total expenses 174.60 544.26] 3.77 554.12] Profit (loss) Before exceptional & Extraordinary items and Tax (1.99) (533.83) (0.77) (537.38) Exceptional items N Profit (loss) from ordinary activities before tax (1.99) (533.83) (0.77) (537.38) Tax Expenses - Current Tax R N (less):- MAT Credit B B B B Current Tax Expense Relating to Prior years - L - - Deferred Tax (Assets)/llabtiitles Profit (loss) from ordinary activities (1.99)] (533.83) (0.77) (537.38) Other Comprehensive Income (OC1) B Items that will not be reclassified to profit or loss -| -] B E Income tax relatintgo items that will not be reclassified to profit or = L - L Itemns that will be reclassified to profit or loss B ] - ] Income tax relating to items that will be reclassified to profit or loss R - -| .| Total Profit After Other Comprehensive Income (1.99) (533.83) (0.77)] (537.38) Profit/(Loss) From Discountinuing Operation Before Tax : Tax Expenses of Discontinuing Operations | Net Profit/(Loss) from Discountinuing Opration After Tax ] ] | ] Profit(Loss) For Period Before Minority Interest g - - - Share Of Profit/ Loss Associates E Profit/Loss Of Minority Interset ] Net Profit (+)/ Loss (-) For the Period (1.99)] (533.83) (0.77) (537.38) Details of equity share capital Paid-up equity share capital 633.00) 633.00] 630,00} 633.00) Face value of equity share capital (per share) 10.00) 10.00] 10.00) 10.00} Reserve Excluding Revaluation Reserves As Par Balance sheet Of previous Year i ' i Earnings per share (EPS) Baassiic c earnings per share from countinuing And Discountinuing (003) 8.43) (0.0) (8.49) operations Diluted earnings per share from countinuing And Discountinuing| operations (0.03)) (8.43) (0.01), (8.49)) Notes:. The above said finanical results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective Meetings 1 held on 14th August , 2026, ~ The Statutory Auditors have carried out limited review of the Unaudited Results of the Compnay for the Quarter ended 30/06/2026. These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time. The Company has three reportable business segment(Pharma, Real Estate & Tea Estate). Hence, separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".& imited For, Nov§oR RURRARA eE unareo N el o Hitno: Sianatory +-14-08-2026 DireGIRHuNar Mohanbhai Amreliya Place: - SURAT Director| UDIN :-26115279VCBPFZ1372 DIN: 11339148 DGM& SCo. Chartered Accountants Hiren J. Maru B.Com.. F.C.A,, DISA. DIRM Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended) To Board of Directors of NOVYRA PHARMACHEM LIMITED (Formerly known as Bansisons Tea Industries Limited) We have reviewed the accompanying Statement of Unaudited Standalone Financial Results Novyra Pharmachem Limted (Formerly known as Bansisons Tea Industries Limited) ("the Company") for the quarter ended [Showing first 8,000 characters — download PDF for full document]